EA201400996A1 - Комбинированная терапия для лечения рака яичника - Google Patents

Комбинированная терапия для лечения рака яичника

Info

Publication number
EA201400996A1
EA201400996A1 EA201400996A EA201400996A EA201400996A1 EA 201400996 A1 EA201400996 A1 EA 201400996A1 EA 201400996 A EA201400996 A EA 201400996A EA 201400996 A EA201400996 A EA 201400996A EA 201400996 A1 EA201400996 A1 EA 201400996A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ovarian cancer
treatment
combined therapy
diagnosed
platinum
Prior art date
Application number
EA201400996A
Other languages
English (en)
Inventor
Коррадо Бернаскони
Давид Боллаг
Original Assignee
Ф.Хоффманн-Ля Рош Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
Priority to US201261610128P priority Critical
Priority to US201261653598P priority
Priority to US201261672987P priority
Application filed by Ф.Хоффманн-Ля Рош Аг filed Critical Ф.Хоффманн-Ля Рош Аг
Priority to PCT/EP2013/054818 priority patent/WO2013135602A2/en
Publication of EA201400996A1 publication Critical patent/EA201400996A1/ru
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47844333&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201400996(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4738Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/127Liposomes
    • A61K9/1271Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q30/00Commerce, e.g. shopping or e-commerce
    • G06Q30/02Marketing, e.g. market research and analysis, surveying, promotions, advertising, buyer profiling, customer management or rewards; Price estimation or determination
    • G06Q30/0241Advertisement
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q90/00Systems or methods specially adapted for administrative, commercial, financial, managerial, supervisory or forecasting purposes, not involving significant data processing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507Comprising a combination of two or more separate antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Abstract

В заявке описаны способы лечения пациента, у которого диагностирован устойчивый к препаратам платины рак яичника, заключающиеся в том, что указанному пациенту вводят в эффективном количестве антитело к VEGF и химиотерапевтическое средство.
EA201400996A 2012-03-13 2013-03-11 Комбинированная терапия для лечения рака яичника EA201400996A1 (ru)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US201261610128P true 2012-03-13 2012-03-13
US201261653598P true 2012-05-31 2012-05-31
US201261672987P true 2012-07-18 2012-07-18
PCT/EP2013/054818 WO2013135602A2 (en) 2012-03-13 2013-03-11 Combination therapy for the treatment of ovarian cancer

Publications (1)

Publication Number Publication Date
EA201400996A1 true EA201400996A1 (ru) 2015-03-31

Family

ID=47844333

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201400996A EA201400996A1 (ru) 2012-03-13 2013-03-11 Комбинированная терапия для лечения рака яичника

Country Status (24)

Country Link
US (2) US20150098988A1 (ru)
EP (1) EP2825558B1 (ru)
JP (2) JP6563197B2 (ru)
KR (1) KR20140138691A (ru)
CN (1) CN104334577A (ru)
AR (1) AR090313A1 (ru)
AU (2) AU2013231410B2 (ru)
CA (1) CA2860941A1 (ru)
CO (1) CO7000770A2 (ru)
CR (1) CR20140400A (ru)
DK (1) DK2825558T3 (ru)
EA (1) EA201400996A1 (ru)
HK (1) HK1202122A1 (ru)
IL (2) IL234174A (ru)
LT (1) LT2825558T (ru)
MX (1) MX365139B (ru)
PE (1) PE19092014A1 (ru)
PH (1) PH12014501543A1 (ru)
RS (1) RS58964B1 (ru)
SG (1) SG11201404417PA (ru)
SI (1) SI2825558T1 (ru)
TW (1) TW201343178A (ru)
WO (1) WO2013135602A2 (ru)
ZA (1) ZA201404843B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017053705A1 (en) * 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
WO2019005754A1 (en) * 2017-06-26 2019-01-03 The Cleveland Clinic Foundation Cancer treatment

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035D0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE69129154D1 (de) 1990-12-03 1998-04-30 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US20030206899A1 (en) 1991-03-29 2003-11-06 Genentech, Inc. Vascular endothelial cell growth factor antagonists
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP1167384B1 (en) 1992-10-28 2006-12-13 Genentech, Inc. HVEGF Receptor as Vascular endothelial cell growth factor antagonists
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
AU716785B2 (en) 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
DE122007000021I1 (de) 1997-04-07 2007-05-24 Genentech Inc Anti-vefg Antibodies
CN1191276C (zh) 1997-04-07 2005-03-02 基因技术股份有限公司 人源化抗体和制备人源化抗体的方法
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
US20020032315A1 (en) 1997-08-06 2002-03-14 Manuel Baca Anti-vegf antibodies
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (da) 1997-12-05 2012-01-30 Scripps Research Inst Humanisering af murint antistof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
AU2002239422B2 (en) 2000-11-30 2006-12-07 E. R. Squibb & Sons, L.L.C. Transgenic transchromosomal rodents for making human antibodies
WO2003102157A2 (en) 2002-06-03 2003-12-11 Genentech, Inc. Synthetic antibody phage libraries
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
AU2004251168A1 (en) 2003-05-30 2005-01-06 Genentech, Inc. Treatment with anti-VEGF antibodies
US20050106667A1 (en) 2003-08-01 2005-05-19 Genentech, Inc Binding polypeptides with restricted diversity sequences
WO2005044853A2 (en) 2003-11-01 2005-05-19 Genentech, Inc. Anti-vegf antibodies
US7527791B2 (en) 2004-03-31 2009-05-05 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
SV2006002143A (es) * 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
US20060009360A1 (en) 2004-06-25 2006-01-12 Robert Pifer New adjuvant composition
US20070166388A1 (en) * 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EP1973951A2 (en) 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
AU2007249408A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20100297216A1 (en) * 2006-12-20 2010-11-25 Gabizon Alberto A Method for administration of pegylated liposomal doxorubicin
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司;群创光电股份有限公司 液晶显示面板驱动装置及其驱动方法
US20110159080A1 (en) * 2008-06-03 2011-06-30 Colin Lowery Composition comprising liposome-entrapped doxorubicin and methods of administration
MX2012009554A (es) * 2010-02-23 2012-11-23 Hoffmann La Roche Terapia anti-angiogenesis para el tratamiento del cancer ovarico.

Also Published As

Publication number Publication date
HK1202122A1 (en) 2015-09-18
CR20140400A (es) 2014-10-07
AU2013231410A1 (en) 2014-07-17
PE19092014A1 (es) 2014-11-29
IL234174A (en) 2019-01-31
JP6563197B2 (ja) 2019-08-21
AR090313A1 (es) 2014-11-05
WO2013135602A3 (en) 2013-11-07
JP2018193380A (ja) 2018-12-06
AU2017258927A1 (en) 2017-11-30
CN104334577A (zh) 2015-02-04
MX2014010591A (es) 2014-09-18
ZA201404843B (en) 2015-08-26
EP2825558A2 (en) 2015-01-21
SG11201404417PA (en) 2014-10-30
DK2825558T3 (da) 2019-07-22
RS58964B1 (sr) 2019-08-30
CA2860941A1 (en) 2013-09-19
US20150098988A1 (en) 2015-04-09
TW201343178A (zh) 2013-11-01
KR20140138691A (ko) 2014-12-04
JP2015511593A (ja) 2015-04-20
IL263781D0 (en) 2019-01-31
SI2825558T1 (sl) 2019-08-30
EP2825558B1 (en) 2019-05-15
WO2013135602A2 (en) 2013-09-19
PH12014501543A1 (en) 2014-10-08
CO7000770A2 (es) 2014-07-21
AU2013231410B2 (en) 2017-08-17
LT2825558T (lt) 2019-08-12
US20160289317A1 (en) 2016-10-06
MX365139B (es) 2019-05-24

Similar Documents

Publication Publication Date Title
BR112014029883A2 (pt) anticorpo totalmente humano, fragmento fab de anticorpo, anticorpo humano de cadeia única e método para tratar um amplo espectro de cânceres.
MX2015011774A (es) Biomarcadores y metodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
BR112013022927A2 (pt) composição, métodos para substituir ou suplementar ou modificar uma microbiota do cólon de um sujeito, e para tratar um sujeito, e, uso de uma composição
EA201790834A1 (ru) Молекулы антител к pd-l1 и их применение
EA201691556A1 (ru) Молекулы антител к tim-3 и их применение
BR112016003394A2 (pt) usos de um antagonista de pd-1 e um agonista do gitr e de um anticorpo biespecífico ou fragmento de ligação do antígeno do mesmo, e, combinação farmacêutica
MX2015003985A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-dp-1 para tratar cancer.
EA201400991A1 (ru) Комбинированная терапия с использованием антител к человеческому csf-1r и ее применения
BR112014024494A2 (pt) dosagem e administração de anticorpos anti-igf-1r e anti-erbb3 monoespecíficos e biespecíficos
MX2015012122A (es) Conjugados de anticuerpo-farmaco y los anticuerpos correspondientes.
EA201790413A1 (ru) Антитела против tigit
MX2016013375A (es) Tratamiento de la hgna y ehna.
MX2016003103A (es) Combinacion de anticuerpos anti-gen 3 de la activacion del linfoncito (lag-3) y anticuerpos anti-muerte celular programada 1 (pd-1) para tratar tumores.
SG10201801433XA (en) Composition and vaccine for treating prostate cancer
MX2017013613A (es) Neoepitodos de cancer.
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
BR112014029888A2 (pt) métodos para a produção de um anticorpo e para a determinação de uma combinação de sítios de ligação, formulação farmacêutica, anticorpo, uso do anticorpo e método de tratamento de um indivíduo com câncer
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
RU2017141448A (ru) Лечение рака путем манипуляций с комменсальной микрофлорой
TN2015000050A1 (en) Methods of treating a tauopathy
BR112015011830A2 (pt) compostos e seus métodos de utilização
EA201291260A1 (ru) Антитело против trop-2 человека, обладающее противоопухолевой активностью in vivo
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
EA201590997A1 (ru) Соединения и способы их применения
EP2744830A4 (en) Lsr antibodies, and uses thereof for treatment of cancer